Prime Medicine (NASDAQ:PRME) Receives Sell (E+) Rating from Weiss Ratings

Key Points

• Prime Medicine (NASDAQ: PRME) has received a "sell (e+)" rating from Weiss Ratings and has an average rating of "Sell" according to MarketBeat.
• The stock was recently downgraded from a "hold" to "sell" rating by Wall Street Zen on September 2nd, indicating a bearish outlook from analysts.
• Prime Medicine's stock saw a significant increase of 9.9% on a recent trading day, with a trading range of $1.11 to $6.94 over the past year.

Prime Medicine (NASDAQ:PRME - Get Free Report)'s stock had its "sell (e+)" rating restated by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded Prime Medicine from a "hold" rating to a "sell" rating in a research note on Tuesday, September 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Prime Medicine has an average rating of "Sell".

Prime Medicine Stock Up 9.9%

PRME stock opened at $6.45 on Wednesday. Prime Medicine has a 1-year low of $1.11 and a 1-year high of $6.94. The company has a market capitalization of $868.00 million, a price-to-earnings ratio of -4.13 and a beta of 2.65.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.